Merck, Pfizer, Eli Lilly, Enlight Biosciences, RainDance Technologies, Znomics, Oregon Health & Science University, Sangamo BioScience, Sigma-Aldrich, Roche, National Cancer Institute, Wellcome Trust Sanger Institute | GenomeWeb
Merck, Pfizer, Lilly Form New Company to Speed Development of Drug-Discovery Tools
 
Merck, Pfizer, and Eli Lilly said this week that they have partnered with PureTech Ventures to create a new firm called Enlight Biosciences that will focus on the development of new drug-discovery technologies.
 
The three pharmas and PureTech have ponied up a total of $39 million that Enlight will direct toward “breakthrough technologies that can fundamentally alter drug discovery and development.”
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.